Medical Breakthroughs Offer New Hope for Children with Rare Diseases
Medical advancements in gene therapy and targeted treatments offer new hope for children battling rare conditions like epidermolysis bullosa, phenylketonuria, and Niemann-Pick disease.

Medical advancements in genetic research, molecular disease mechanisms, and targeted therapies are transforming the landscape for children battling complex, rare, and chronic medical conditions. Marking International Children Day, pediatric specialists and patient advocacy groups highlight both the daily struggles of affected families and the emerging breakthroughs offering new hope.
Epidermolysis Bullosa: Managing Severe Skin Fragility
Epidermolysis Bullosa, commonly known as butterfly skin disease, encompasses a group of rare genetic conditions characterized by extreme skin fragility. In severe cases such as recessive dystrophic epidermolysis bullosa, genetic mutations impair the connection between skin layers, causing recurrent blistering, painful wounds, infections, and scarring. Professor Liat Samuelov, head of the pediatric dermatology unit and the multidisciplinary epidermolysis bullosa clinic at the Tel Aviv Sourasky Medical Center (Ichilov), explains that affected children endure chronic wounds and systemic complications.
"Children with severe forms of epidermolysis bullosa live in a harsh reality of chronic wounds and ulcers involving the skin and mucous membranes, accompanied by pain and severely compromised quality of life," Professor Samuelov emphasizes.
Recent scientific breakthroughs include gene therapies and topical gels that stimulate skin cells to produce type 7 collagen, addressing the molecular root cause rather than merely treating wounds post-formation.
Phenylketonuria: Navigating Strict Dietary Restrictions
For children with phenylketonuria, a hereditary metabolic disorder where the body cannot break down the amino acid phenylalanine, everyday foods present significant health risks. Undiagnosed or unmanaged, the condition leads to irreversible cognitive impairment. While newborn screening in Israel enables early detection, daily management requires strict dietary limitations, specialized medical nutrition, and continuous blood testing. Attorney Noga-Michal Nadab, chair of the Golden Children Association, notes the emotional toll of seeing a child hungry and unable to eat freely. Pediatrician and geneticist Dr. Joshua Manor points out that emerging pharmacological treatments help reduce blood phenylalanine levels, granting patients greater dietary flexibility.
Niemann-Pick Type C: Confronting Neurodegenerative Decline
Niemann-Pick disease type C is a rare, severe metabolic condition caused by impaired cholesterol and lipid transport within cells, leading to progressive neurological deterioration. Pediatricians note that children may lose acquired milestones such as walking, speech, and cognitive functions. Professor Orna Staretz-Chacham, head of the pediatric rare diseases center at the Saban Children Hospital in Soroka, highlights that newly approved treatments in the USA target neurological manifestations, demonstrating measurable clinical improvements in patients.
Vitiligo: Addressing Psychological and Social Impact
Yahav Lavi, founder and CEO of the Vitiligo Association in Israel, underscores that chronic autoimmune conditions affecting appearance, such as vitiligo, present severe social and self-esteem challenges for children and teenagers navigating identity formation. Despite differing etiologies, these conditions share a common imperative: advancing medical science to reduce pain, improve daily functioning, and safeguard a normal childhood.





